Biogen Price Target Maintained With a $292.00/Share by RBC Capital
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292
RBC Capital analyst Brian Abrahams maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $292.According to TipRanks data, the analyst has a success rate of 49.7% and a
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Express News | Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months
Express News | Biogen Exec Says Co Expects Immunogenicity Data to Be Ready by October to Submit to FDA for Subcutaneous Leqembi Filing - Cantor Fitzgerald Conference
Express News | Biogen Canada: Regulatory Decision on New Drug Submission for Omaveloxolone Is Anticipated in Early 2025
Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
Here's Why Biogen Inc. (BIIB) Is a Strong Value Stock
Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen
US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Jones Research Starts Larimar at Buy, Cites Lead Asset Nomlabofusp
Healthcare Stocks Have Popped. Consider These 2 That Haven't. -- Barrons.com
Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB
Express News | Biogen Board Appoints Two New Independent Directors
Press Release: Biogen Board Appoints Two New Independent Directors
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Express News | Bio-Thera Solutions: Comparable Clinical Efficacy, Safety in Treatment Period 2 Is Maintained After Switch From Reference Tocilizumab to Tofidence
Express News | Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for Tofidence™